Yuji Yamanishi
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yuji Yamanishi.
Cell | 2003
Thorsten Cramer; Yuji Yamanishi; Björn E. Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H. Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S. Firestein; Hans Gerber; Napoleone Ferrara; Randall S. Johnson
Granulocytes and monocytes/macrophages of the myeloid lineage are the chief cellular agents of innate immunity. Here, we have examined the inflammatory response in mice with conditional knockouts of the hypoxia responsive transcription factor HIF-1alpha, its negative regulator VHL, and a known downstream target, VEGF. We find that activation of HIF-1alpha is essential for myeloid cell infiltration and activation in vivo through a mechanism independent of VEGF. Loss of VHL leads to a large increase in acute inflammatory responses. Our results show that HIF-1alpha is essential for the regulation of glycolytic capacity in myeloid cells: when HIF-1alpha is absent, the cellular ATP pool is drastically reduced. The metabolic defect results in profound impairment of myeloid cell aggregation, motility, invasiveness, and bacterial killing. This role for HIF-1alpha demonstrates its direct regulation of survival and function in the inflammatory microenvironment.
Proceedings of the National Academy of Sciences of the United States of America | 2002
Yuji Yamanishi; David L. Boyle; Sanna Rosengren; Douglas R. Green; Nathan J. Zvaifler; Gary S. Firestein
The p53 tumor suppressor protein plays a central role in cell cycle regulation, DNA repair, and apoptosis. Recent studies indicate that DNA damage and somatic mutations in the p53 gene can occur because of genotoxic stress in many tissues, including the skin, colon, and synovium. Although somatic mutations in the p53 gene have been demonstrated in rheumatoid arthritis (RA) synovial tissue and synoviocytes, no information is available on the location or extent of p53 mutations. Using microdissected RA synovial tissue sections, we observed abundant p53 transition mutations, which are characteristic DNA damage caused by oxidative stress. p53 mutations, as well as p53 mRNA expression, were located mainly in the synovial intimal lining rather than the sublining (P < 0.01). Clusters of p53 mutant subclones were observed in some microdissected regions, suggesting oligoclonal expansion. Because IL-6 gene expression is regulated by wild-type p53, IL-6 mRNA expression in microdissected tissues was quantified by using real-time PCR. The regions with high rates of p53 mutations contained significantly greater amounts of IL-6 mRNA compared with the low mutation samples (P < 0.02). The microdissection findings suggest that p53 mutations are induced in RA synovial tissues by inflammatory oxidative stress. This process, as in sun-exposed skin and inflamed colonic epithelium, provides some of the mutant clones with a selective growth advantage. A relatively low percentage of cells containing p53 mutations can potentially affect neighboring cells and enhance inflammation through the elaboration of proinflammatory cytokines.
Journal of Immunology | 2002
Yuji Yamanishi; David L. Boyle; Melody Clark; Rich A. Maki; Micky D. Tortorella; Elizabeth C. Arner; Gary S. Firestein
Aggrecanases are key matrix-degrading enzymes that act by cleaving aggrecan at the Glu373-Ala374 site. While these fragments have been detected in osteoarthritis (OA) and rheumatoid arthritis (RA) cartilage and synovial fluid, no information is available on the regulation or expression of the two key aggrecanases (aggrecanase-1 and aggrecanase-2) in synovial tissue (ST) or fibroblast-like synoviocytes (FLS). The aggrecanase-1 gene was constitutively expressed by both RA and OA FLS. Real-time PCR demonstrated that TGF-β significantly increased aggrecanase-1 gene expression in FLS. Aggrecanase-1 induction peaked after 24 h of TGF-β stimulation. The expression of aggrecanase-1 mRNA was significantly greater in RA ST than in OA or nonarthritis ST. Aggrecanase-2 mRNA and protein were constitutively produced by nonarthritis, OA, and RA FLS but were not increased by IL-1, TNF-α, or TGF-β. Furthermore, OA, RA, and nonarthritis ST contained similar amounts of immunoreactive aggrecanase-2. The major form of the aggrecanase-2 enzyme was 70 kDa in nonarthritis ST, whereas a processed 53-kDa form was abundant in RA ST. Therefore, aggrecanase-1 and -2 are differentially regulated in FLS. Both are constitutively expressed, but aggrecanase-1 is induced by cytokines, especially TGF-β. In contrast, aggrecanase-2 protein may be regulated by a post-translational mechanism in OA and RA ST. Synovial and FLS production of aggrecanase can contribute to cartilage degradation in RA and OA.
American Journal of Pathology | 2002
Yuji Yamanishi; David L. Boyle; Michael J. Pinkoski; Artin Mahboubi; Tesu Lin; Zuoning Han; Nathan J. Zvaifler; Douglas R. Green; Gary S. Firestein
The role of the tumor suppressor p53 as a key regulator of inflammation was examined in murine collagen-induced arthritis (CIA), a model of rheumatoid arthritis. Wild-type DBA/1 mice develop progressive arthritis in this model, in which p53 expression and apoptosis are evident in the synovial cells. In contrast, the joints of p53(-/-) DBA/1 animals with CIA showed increased severity of arthritis using clinical and histological scoring methods with almost no apoptosis. Consistent with this, collagenase-3 expression and cytokine production (interleukin-1 and interleukin-6) in the joints of p53(-/-) mice with CIA were significantly greater than in wild-type mice. Anti-collagen antibody titers, however, were not different. Therefore, p53 expression occurs during inflammation and acts to suppress local inflammatory responses. Because mutations in p53 have been described in the synovial membrane of rheumatoid arthritis patients, the loss of p53 function in synoviocytes or other cells in the joint because of dominant-negative mutations might contribute to invasion and destruction of the joint in this disease.
Rheumatic Diseases Clinics of North America | 2001
Yuji Yamanishi; Gary S. Firestein
Arthritis & Rheumatism | 2002
Zuoning Han; Lufen Chang; Yuji Yamanishi; Michael Karin; Gary S. Firestein
Cellular Immunology | 2001
Karlfried R. Aupperle; Yuji Yamanishi; Brydon L. Bennett; Frank Mercurio; David L. Boyle; Gary S. Firestein
Arthritis Research & Therapy | 2005
Yuji Yamanishi; David L. Boyle; Douglas R. Green; Edward C. Keystone; Alison Connor; Susan Zollman; Gary S. Firestein
Clinical and Experimental Rheumatology | 2008
Toshiko Ito-Ihara; Eri Muso; Shigeto Kobayashi; Kazuko Uno; N. Tamura; Yuji Yamanishi; Atsushi Fukatsu; Richard A. Watts; Dgi Scott; D Jayne; Kazuo Suzuki; Hiroshi Hashimoto
Cell | 2003
Thorsten Cramer; Yuji Yamanishi; Björn E. Clausen; Irmgard Förster; Rafal Pawlinski; Nigel Mackman; Volker H. Haase; Rudolf Jaenisch; Maripat Corr; Victor Nizet; Gary S. Firestein; Hans Gerber; Napoleone Ferrara; Randall S. Johnson